A Trial of Solriamfetol in the Treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
Status:
Not yet recruiting
Trial end date:
2022-01-01
Target enrollment:
Participant gender:
Summary
This study is an 8-week single center, randomized, double-blind, placebo-controlled, flexible
titration trial evaluating the efficacy of solriamfetol in the treatment of fatigue symptoms
in adult patients with chronic fatigue syndrome. Subjects will be randomized to a
solriamfetol group or placebo group. The investigators will utilize an intent to treat model
and impute data. The overall goal of this study is to determine the efficacy and
effectiveness of solriamfetol for treating chronic fatigue syndrome.